铂类耐药的伴体力状态 2/3 的尿路上皮癌患者接受每周低剂量吉西他滨联合紫杉醇治疗。
Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3.
机构信息
Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
出版信息
In Vivo. 2019 Nov-Dec;33(6):2217-2224. doi: 10.21873/invivo.11725.
BACKGROUND/AIM: Immune check-point inhibitors are often unsuitable for patients with urothelial cancer with a poor performance status (PS 2 or 3). The aim of this study was to assess the safety and usefulness of combined therapy with low-dose gemcitabine and paclitaxel every 4 weeks.
PATIENTS AND METHODS
Thirty patients were treated with gemcitabine (700 mg/m on day 1) and paclitaxel (70 mg/m on day 1) every 4 weeks. The predictive value of human antigen-R (HuR) and class III β-tubulin (TUBB3) were also analyzed.
RESULTS
There was no severe adverse event nor significant decrease in quality of life. The survival period of patients treated with this regimen was significantly longer than that of those treated with best supportive care. The expression pattern of HuR negativity and TUBB3 positivity predicted significantly worse overall survival.
CONCLUSION
Our regimen was suitable as second-line therapy for patients with advanced platinum-resistant UC with a poor PS. However, a HuR-negative and TUBB3-positive expression pattern appears to confer poorer outcome.
背景/目的：免疫检查点抑制剂通常不适合身体状况不佳（PS 2 或 3）的尿路上皮癌患者。本研究旨在评估低剂量吉西他滨和紫杉醇每 4 周联合治疗的安全性和有效性。
患者和方法
30 名患者接受吉西他滨（第 1 天 700mg/m）和紫杉醇（第 1 天 70mg/m）每 4 周治疗。还分析了人抗原-R（HuR）和 III 类 β-微管蛋白（TUBB3）的预测价值。
结果
无严重不良事件，生活质量无明显下降。接受该方案治疗的患者的生存期明显长于接受最佳支持治疗的患者。HuR 阴性和 TUBB3 阳性的表达模式预测总生存期明显更差。
结论
我们的方案适用于身体状况不佳的晚期铂类耐药 UC 患者的二线治疗。然而，HuR 阴性和 TUBB3 阳性的表达模式似乎预示着更差的预后。
Zotero 插件